During the past decade, Hiroshima City Hiroshima Citizens Hospital conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 20 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 13 clinical trials were completed. i.e. 68.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hiroshima City Hiroshima Citizens Hospital" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Bayer" with 5 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Haruhiko Fukuda" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hiroshima City Hiroshima Citizens Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator and "Japan Lung Cancer Society" with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Hiroshima City Hiroshima Citizens Hospital" are "Breast Cancer" (8 trials), "Breast Neoplasms" (4 trials), "Migraine" (4 trials), "Atrial Fibrillation" (2 trials) and "Gastric Neoplasm" (2 trials). Many other conditions were trialed in "Hiroshima City Hiroshima Citizens Hospital" in a lesser frequency.

Most popular intervention types in "Hiroshima City Hiroshima Citizens Hospital" are "Drug" (43 trials), "Other" (8 trials), "Procedure" (4 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Paclitaxel" (8 trials), "Cyclophosphamide" (6 trials), "Doxorubicin" (5 trials) and "Trastuzumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima City Hiroshima Citizens Hospital" are 45 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hiroshima City Hiroshima Citizens Hospital". undefined are not yet recruiting, 17 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Hiroshima City Hiroshima Citizens Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima City Hiroshima Citizens Hospital, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Hiroshima City Hiroshima Citizens Hospital has several departments that took part in Clinical trials: "Hiroshima City Hiroshima Citizens Hospital; Urology" - 2 trials